Literature DB >> 20200429

Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.

Eva S Schernhammer1, Franco Berrino, Vittorio Krogh, Giorgio Secreto, Andrea Micheli, Elisabetta Venturelli, Sara Grioni, Christopher T Sempos, Adalberto Cavalleri, Holger J Schünemann, Sabrina Strano, Paola Muti.   

Abstract

BACKGROUND: Lower urinary melatonin levels are associated with a higher risk of breast cancer in postmenopausal women. Literature for premenopausal women is scant and inconsistent.
METHODS: In a prospective case-control study, we measured the concentration of 6-sulphatoxymelatonin (aMT6s) in the 12-hour overnight urine of 180 premenopausal women with incident breast cancer and 683 matched controls.
RESULTS: In logistic regression models, the multivariate odds ratio (OR) of invasive breast cancer for women in the highest quartile of total overnight aMT6s output compared with the lowest was 1.43 [95% confidence interval (CI), 0.83-2.45; P(trend) = 0.03]. Among current nonsmokers, no association was existent (OR, 1.00; 95% CI, 0.52-1.94; P(trend) = 0.29). We observed an OR of 0.68 between overnight urinary aMT6s level and breast cancer risk in women with invasive breast cancer diagnosed >2 years after urine collection and a significant inverse association in women with a breast cancer diagnosis >8 years after urine collection (OR, 0.17; 95% CI, 0.04-0.71; P(trend) = 0.01). There were no important variations in ORs by tumor stage or hormone receptor status of breast tumors.
CONCLUSION: Overall, we observed a positive association between aMT6s and risk of breast cancer. However, there was some evidence to suggest that this might be driven by the influence of subclinical disease on melatonin levels, with a possible inverse association among women diagnosed further from recruitment. Thus, the influence of lag time on the association between melatonin and breast cancer risk needs to be evaluated in further studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200429      PMCID: PMC2837369          DOI: 10.1158/1055-9965.EPI-09-1229

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  45 in total

Review 1.  Role of vitamins in the risk, prevention, and treatment of breast cancer.

Authors:  Shumin M Zhang
Journal:  Curr Opin Obstet Gynecol       Date:  2004-02       Impact factor: 1.927

2.  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.

Authors:  Sebastian Härtter; Anna Nordmark; Dirk-Matthias Rose; Leif Bertilsson; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 3.  Circadian and sleep-dependent regulation of hormone release in humans.

Authors:  C A Czeisler; E B Klerman
Journal:  Recent Prog Horm Res       Date:  1999

4.  [Serum creatinine determination without protein precipitation].

Authors:  H Bartels; M Böhmer; C Heierli
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

5.  Increased breast cancer risk among women who work predominantly at night.

Authors:  J Hansen
Journal:  Epidemiology       Date:  2001-01       Impact factor: 4.822

Review 6.  Melatonin: from basic research to cancer treatment clinics.

Authors:  Charles R Thomas; Russel J Reiter; Terence S Herman
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 7.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Authors:  Carey K Anders; Lisa A Carey
Journal:  Clin Breast Cancer       Date:  2009-06       Impact factor: 3.225

8.  Night shift work, light at night, and risk of breast cancer.

Authors:  S Davis; D K Mirick; R G Stevens
Journal:  J Natl Cancer Inst       Date:  2001-10-17       Impact factor: 13.506

9.  Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.

Authors:  E S Schernhammer; F Laden; F E Speizer; W C Willett; D J Hunter; I Kawachi; G A Colditz
Journal:  J Natl Cancer Inst       Date:  2001-10-17       Impact factor: 13.506

10.  Melatonin and breast cancer: a prospective study.

Authors:  Ruth C Travis; Diane S Allen; Ian S Fentiman; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

View more
  29 in total

1.  Sleep duration, spot urinary 6-sulfatoxymelatonin levels and risk of breast cancer among Chinese women in Singapore.

Authors:  Anna H Wu; Frank Z Stanczyk; Renwei Wang; Woon-Puay Koh; Jian-Min Yuan; Mimi C Yu
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

2.  Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.

Authors:  Elizabeth E Devore; Erica T Warner; A Heather Eliassen; Susan B Brown; Andrew H Beck; Susan E Hankinson; Eva S Schernhammer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-09       Impact factor: 4.254

3.  Moderate alcohol consumption and 24-hour urinary levels of melatonin in postmenopausal women.

Authors:  T J Hartman; S Mahabir; D J Baer; R G Stevens; P S Albert; J F Dorgan; J S Kesner; J W Meadows; R Shields; P R Taylor
Journal:  J Clin Endocrinol Metab       Date:  2011-10-19       Impact factor: 5.958

4.  A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.

Authors:  E S Schernhammer; A Giobbie-Hurder; K Gantman; J Savoie; R Scheib; L M Parker; W Y Chen
Journal:  Cancer Causes Control       Date:  2012-02-28       Impact factor: 2.506

Review 5.  Circadian disrupting exposures and breast cancer risk: a meta-analysis.

Authors:  Chunla He; Sonia Taj Anand; Mark H Ebell; John E Vena; Sara Wagner Robb
Journal:  Int Arch Occup Environ Health       Date:  2014-09-27       Impact factor: 3.015

6.  Urinary melatonin concentration and the risk of breast cancer in Nurses' Health Study II.

Authors:  Susan B Brown; Susan E Hankinson; A Heather Eliassen; Katherine W Reeves; Jing Qian; Kathleen F Arcaro; Lani R Wegrzyn; Walter C Willett; Eva S Schernhammer
Journal:  Am J Epidemiol       Date:  2015-01-13       Impact factor: 4.897

7.  Shedding light on the role of circadian disruption in breast cancer etiology.

Authors:  Pagona Lagiou
Journal:  Eur J Epidemiol       Date:  2016-08-22       Impact factor: 8.082

Review 8.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

9.  Rotating night-shift work and lung cancer risk among female nurses in the United States.

Authors:  Eva S Schernhammer; Diane Feskanich; Geyu Liang; Jiali Han
Journal:  Am J Epidemiol       Date:  2013-09-18       Impact factor: 4.897

Review 10.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.

Authors:  Olga Golubnitschaja; Manuel Debald; Kristina Yeghiazaryan; Walther Kuhn; Martin Pešta; Vincenzo Costigliola; Godfrey Grech
Journal:  Tumour Biol       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.